Angiosyn

Angiosyn Inc. develops novel proprietary biologics to control angiogenesis. The company’s initial therapeutic indications are ophthalmic diseases, such as macular degeneration and diabetic retinopathy, where angiogenesis can lead to vision loss and blindness.